Program
danuglipron
Also written as “PF-06882961”, “Danuglipron” and “PF-06882961 (Cohorts 1 and 2)”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by Pfizer.
Drug pageDanuglipron: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 180 open or running | phase 2since Jun 11, 2019 | Oct 10, 2017 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Oct 10, 2017.
- May 7, 2018Phase 1 study in Diabetes Mellitus, Type 2NCT03538743 · 98 enrolled · United States
- Jun 11, 2019Phase 2 study in Diabetes Mellitus, Type 2NCT03985293 · 412 enrolled · United States, Bulgaria, Canada and more
- Jul 16, 2020Phase 1 study in Healthy VolunteerNCT04495140 · 6 enrolled · Netherlands
- Sep 11, 2020Phase 1 study in Diabetes Mellitus, Type 2NCT04552470 · 37 enrolled · Japan
- Oct 21, 20203 phase 1 studiesNCT04604496, NCT04616027, NCT04616339
- Oct 30, 2020Phase 2 study in Diabetes MellitusNCT04617275 · 151 enrolled · United States
- Nov 3, 2020Phase 1 study in ObesityNCT04621227 · 16 enrolled · United States
- Dec 19, 2020Named danuglipronINNProposed as its International Nonproprietary Name in WHO's List 124 · before, PF-06882961
- Jan 11, 2021Phase 2 study in ObesityNCT04707313 · 628 enrolled · United States, Canada, Japan and more
- Mar 29, 2021Phase 1 study in Healthy VolunteerNCT04839393 · 27 enrolled · United States
- May 12, 2021Phase 1 study in Diabetes Mellitus, Type 2NCT04889157 · 20 enrolled · China
- Oct 13, 2021Phase 1 study in Healthy AdultsNCT05093205 · 35 enrolled · United States
- Nov 22, 2023Phase 1 study in Healthy ParticipantsNCT06153758 · 33 enrolled · United States
- Aug 21, 2024Phase 1 study in ObesityNCT06568731 · 23 enrolled · United States
- Mar 12, 2025Phase 1 study in OverweightNCT06910839 · 21 enrolled · United States
TargetBeta
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06910839Overweight · United States | 1 | Terminated | May 1, 2025 | 21 |
| NCT06568731Obesity · United States | 1 | Completed | Dec 18, 2024 | 23 |
| NCT06153758Healthy Participants · United States | 1 | Completed | Sep 30, 2024 | 33 |
| NCT05093205Healthy Adults · United States | 1 | Completed | Jul 6, 2022 | 35 |
| NCT04889157Diabetes Mellitus, Type 2 · China | 1 | Completed | Feb 17, 2022 | 20 |
| NCT04839393Healthy Volunteer · United States | 1 | Completed | Oct 10, 2021 | 27 |
| NCT04707313Obesity · United States, Canada, Japan and more | 2 | Completed | Sep 13, 2023 | 628 |
| NCT04621227Obesity · United States | 1 | Completed | May 13, 2021 | 16 |
| NCT04617275Diabetes Mellitus · United States | 2 | Completed | Nov 17, 2021 | 151 |
| NCT04616339Overweight and/or Obesity · Belgium | 1 | Completed | Jul 19, 2021 | 31 |
| NCT04616027Diabetes Mellitus, Type 2 · United States | 1 | Completed | Feb 18, 2022 | 42 |
| NCT04604496Hepatic Impairment · United States | 1 | Completed | Jan 10, 2022 | 24 |
| NCT04552470Diabetes Mellitus, Type 2 · Japan | 1 | Completed | Mar 25, 2021 | 37 |
| NCT04495140Healthy Volunteer · Netherlands | 1 | Completed | Oct 15, 2020 | 6 |
| NCT03985293Diabetes Mellitus, Type 2 · United States, Bulgaria, Canada and more | 2 | Completed | Jun 8, 2021 | 412 |
| NCT03538743Diabetes Mellitus, Type 2 · United States | 1 | Completed | May 23, 2019 | 98 |
| NCT03492697Healthy Subjects · United States | 1 | Completed | Jul 18, 2018 | 12 |
| NCT03309241Healthy Subjects · United States | 1 | Completed | Feb 21, 2018 | 25 |
How it is read
Names in the registry
- “PF-06882961”, 16 entries
- “Danuglipron”, 2 entries
- “PF-06882961 (Cohorts 1 and 2)”, 1 entry
- “PF-06882961 (Cohort 3)”, 1 entry
- “PF-06882961 20 mg”, 1 entry
Codes read as this program: PF06882961.
Conditions, from the studies’ own filings
- Obesity, 5 studies
- Diabetes Mellitus, Type 2, 5 studies
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.